



JW

ATTORNEY DOCKET NO.: 2002834-0232 (Bacterial Delivery DIV2)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Caplan Examiner: Huynh
Serial No.: 10/728,323 Art Unit: 1644
Filing Date: December 4, 2003
Title: MICROBIAL DELIVERY SYSTEM

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed are the following documents:

1. Form PTO-1449 (10 pages);
2. Supplemental Information Disclosure Statement (5 pages);
3. Transmittal Letter (1 page);
4. Limited Recognition Under 37 CFR § 10.9(b); and
5. Return Postcard.

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.

Respectfully submitted,

Charles E. Lyon, D.Phil
Agent for Applicant
Limited Recognition Under 37 CFR §10.9(b)

Choate, Hall & Stewart
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000

Dated: 10/22/04

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/22/04 Sandra Saccoccia

Date Signature

Sandra Saccoccia

Typed or Printed Name of person signing certificate



ATTORNEY DOCKET NO.: 2002834-0232 (Bacterial Delivery DIV2)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Caplan

Examiner: Huynh

Serial No.: 10/728,323

Art Unit: 1644

Filing Date: December 4, 2003

Title: MICROBIAL DELIVERY SYSTEM

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

- An *original* Information Disclosure Statement; or
 A *supplemental* Information Disclosure Statement.

Certificate of Mailing

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/22/04
Date

Sandra Saccoccia
Signature

Sandra Saccoccia
Name of Person Signing

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

- [X] Pursuant to 37 CFR § 1.97(b); no fee or certification is required:
- [] Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
- [] Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
- [X] Before the mailing of a first Office action on the merits; or
- [] Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- [] Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:
- [] Certifies that *either*:
- [] each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
- [] That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual

designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement; or

- [] Includes herewith the fee set forth in § 1.17(p),
- [] Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:
 - [] Certifies that *either*:
 - [] each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
 - [] That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement; and
 - [] Includes herewith the fee set forth in § 1.17(p).

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- [] A copy of each cited reference not indicated with an asterisk is included;
- [X] Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status
09/731,375	December 6, 2000	Published

- [] Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

- [X] Does not contain non-English language citations;
- [] Includes one or more translations of a non-English citation; or
- [] Does contain non-English language citations, of which the following is a concise explanation:

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 USC §102.


It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,


Dated: 10/22/04



Charles E. Lyon, D.Phil.
Agent for Applicant
Limited Recognition Under 37 CFR §10.9(b)

CHOATE, HALL & STEWART
Exchange Place
53 State Street
Boston, Massachusetts 02109
(617) 248-5000
(617) 248-4000

PTO-1449
(REV. 8-83)



U.S. Department of
Commerce
Patent and Trademark Office

ATTY. DOCKET:
2002834-0232

IN RE
APPLICATION NO.:
10/728,323

APPLICANT: Caplan

FILING DATE:
December 4, 2003

GROUP: 1644

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**
(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass

U.S. PATENT APPLICATIONS

Examiner's Initials:	Serial Number:	Applicant:	Publication Date:	Group:	Art Unit:


FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No

OTHER DOCUMENTS

Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)
	*Amorim, et al., "Suppression of Airway Eosinophilia by Killed Mycobacterium Vaccae-Induced Allergen-Specific Regulatory T-Cells", <i>Nature Medicine</i> , 8(6): 625-629, 2002.
	*Asturias, et al., "Is Tropomyosin an Allergen in Anisakis?", <i>Allergy</i> , 55: 898-890, 2000.
	*Asturias, et al., "Cloning, Isolation, and IgE-Binding Properties of Helixaspersa (Brown Garden Snail) Tropomyosin", <i>Int. Arch Allergy Immunol.</i> 128: 90-96, 2002.
	*Asturias, et al., "Molecular Characterization of American Cockroach Tropomyosin (Periplaneta Americana Allergen 7), a Cross-Reactive Allergen", <i>The Journal of Immunology</i> , 162: 4342-4348, 1999.
	*Bannon, et al., "Engineering, Characterization and in Vitro Efficacy of the Major Peanut Allergens for Use in Immunotherapy", <i>Int. Arch. Allergy Immunol.</i> 124: 70-72, 2001.
	*Barberas, et al., "Identification and Characterization of Che a 1 Allergen from Chenopodium Album Pollen", <i>Int. Arch. Allergy Immunol.</i> 127: 47-54, 2002.

PTO-1449
(REV. 8-83)



U.S. Department of
Commerce
Patent and Trademark Office

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**
(Use several sheets if necessary)

ATTY. DOCKET:
2002834-0232

IN RE
APPLICATION NO.:
10/728,323

APPLICANT: Caplan

FILING DATE:
December 4, 2003

GROUP: 1644

*Barnes, P.J., "IL-10: A Key Regulator of Allergic Disease", *Clinical and Experimental Allergy*, **31**: 667-669, 2001.

*Bashir, et al., "An Enteric Helminth Infection Protects Against an Allergic Response to Dietary Antigen", *The Journal of Immunology*, **169**: 3284-3292, 2002.

*Batanero, et al., "Purification, Amino Acid Sequence and Immunological Characterization of Ole e 6, a Cysteine-Enriched Allergen from Olive Tree Pollen", *FEBS Letters*, **410**: 293-296, 1997.

*Beck, et al., "The Polyclonal and Antigen-Specific IgE and IgG Subclass Response of Mice Injected with Ovalbumin in Alum or Complete Freund's Adjuvant", *Cellular Immunology*, **123**: 1-8, 1989.

*Bissonnette, et al., "Inhibition of Mast Cell-Mediated Cytotoxicity by IFN- α/β and - γ^1 ", *The Journal of Immunology*, **145**: 3385-3390, 1990.

*Bock, et al., "The Natural History of Food Sensitivity", *J. Allergy Clin. Immunol.* **69**: 173-177, 1982.

*Bock, et al., "Fatalities Due to Anaphylactic Reactions to Foods", *J. Allergy Clin. Immunol.* **107**: 191-193, 2001.

*Brandtzaeg, et al., "Current Understanding of Gastrointestinal Immunoregulation and Its Relation to Food Allergy", *Ann. N.Y. Acad. Sci.*, **964**: 13-45, 2002.

*Burks, et al., "Modification of a Major Peanut Allergen Leads to Loss of IgE Binding", *Int. Arch. Allergy Immunol.* **118**: 313-314, 1999.

*Bush, et al., "Molecular Cloning of a Major Alternaria Alternata Allergen, rAlt a 2", *J. Allergy Clin. Immunol.* **104**: 665-671, 1999.

*Chang, et al., "Characterization of Enolase Allergen from Rhodotorula Mucilaginosa", *J. Biomed. Sci.* **9**: 645-655, 2002.

*Dandeu, et al., "Hydrophobic Interaction Chromatography for Isolation and Purification of Equ.c1, the Horse Major Allergen", *Journal of Chromatography*, **621**: 23-31, 1993.

*De Jong, et al., "Identification and Partial Characterization of Multiple Major Allergens in Peanut Proteins", *Clinical and Experimental Allergy*, **28**: 743-751, 1998.

PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0232	IN RE APPLICATION NO.: 10/728,323
		APPLICANT: Caplan	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		FILING DATE: December 4, 2003	GROUP: 1644
<p>*Diaz-Perales, et al., "Lipid-Transfer Proteins as Potential Plant Panallergens: Cross-Reactivity Among Proteins of Artemisia Pollen, Castanea Nut and Rosaceae Fruits, with Different IgE-Binding Capacities", <i>Clinical and Experimental Allergy</i>, 30: 1403-1410, 2000.</p>			
<p>*Diaz-Perales, et al., "Characterization of Asparagus Allergens: A Relevant Role of Lipid Transfer Proteins", <i>J. Allergy Clin. Immunol.</i> 110: 790-796, 2002.</p>			
<p>*Dorion, et al., "The Production of Interferon-γ in Response to a Major Peanut Allergy, Ara h II, Correlates with Serum Levels of IgE Anti-Ara h II", <i>J. Allergy Clin. Immunol.</i> 93: 93-99, 1994.</p>			
<p>*Durham, et al., "Immunologic Changes Associated with Allergen Immunotherapy", <i>The Journal of Allergy and Clinical Immunology</i>, 102(2): 157-164, 1998.</p>			
<p>*Erb, et al., "Atopic Disorders: A Default Pathway in the Absence of Infection?", <i>Immunol. Today</i>, 20: 317-322, 1999.</p>			
<p>*Eriksson, et al., "Cloning and Characterisation of a Group II Allergen from the Dust Mite Tyrophagus Putrescentiae", <i>Eur. J. Biochem.</i> 251: 443-447, 1998.</p>			
<p>*Eriksson, et al., "Cloning of Three New Allergens from the Dust Mite Lepidoglyphus Destructor Using Phage Surface Display Technology", <i>Eur. J. Biochem.</i> 268: 287-294, 2001.</p>			
<p>*Fahlbusch, et al., "Purification and Partial Characterization of the Major Allergen, Cav p 1, from Guinea Pig <i>Cavia Porcellus</i>", <i>Allergy</i>, 57: 417-422, 2002.</p>			
<p>*Fiorentino, et al., "Two Types of Mouse T Helper Cell", <i>J. Exp. Med.</i> 170: 2081-2095, 1989.</p>			
<p>*Francis, et al., "Induction of IL-10$^+$CD4$^+$CD25$^+$ T Cells by Grass Pollen Immunotherapy", <i>J. Allergy Clin. Immunol.</i> 111: 1255-1261, 2003.</p>			
<p>*Gafvelin, et al., "Cross-Reactivity Studies of a New Group 2 Allergen from the Dust Mite Glycyphagus Domesticus, Gly d 2, and Group 2 Allergens from Dermatophagoides Pteronyssinus, Lepidoglyphus Destructor, and Tyrophagus Putrescentiae with Recombinant Allergens", <i>J. Allergy Clin. Immunol.</i> 107: 511-518, 2001.</p>			
<p>*Giuliani, et al., "Isolation and Purification of a Major Allergen from <i>Parietaria Officinalis</i> Pollen", <i>Allergy</i>, 42: 434-440, 1987.</p>			

PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0232	IN RE APPLICATION NO.: 10/728,323
		APPLICANT: Caplan	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		FILING DATE: December 4, 2003	GROUP: 1644
<p>*Hansen, et al., "Vaccination with Heat-Killed Listeria as Adjuvant Reverses Established Allergen-Induced Airway Hyperreactivity and Inflammation: Role of CD8⁺ T Cells and IL-18", <i>The Journal of Immunology</i>, 164: 223-230, 2000.</p> <p>*Helm, et al., "Isolation and Characterization of a Clone Encoding a Major Allergen (Bla g Bd90K) Involved in IgE-Mediated Cockroach Hypersensitivity", <i>J. Allergy Clin. Immunol.</i> 98: 172-180, 1996.</p> <p>*Hilger, et al., "Sequence of the Gene Encoding cat (<i>Felis Domesticus</i>) Serum Albumin", <i>Gene</i>, 169: 295-296, 1996.</p> <p>*Himly, et al., "Art v 1, the Major Allergen of Mugwort Pollen, is a Modular Glycoprotein with a Defensin-Like and a Hydroxyproline-Rich Domain", <i>FASEB J.</i>, 17: 106-108, 2003.</p> <p>*Hoffman, et al., "Occupational Allergy to Bumblebees: Allergens of <i>Bombus Terrestris</i>", <i>J. Allergy Clin. Immunol.</i> 108: 855-860, 2001.</p> <p>*Hoffman, et al., "Allergens in Hymenoptera Venom XXVII: Bumblebee Venom Allergy and Allergens", <i>J. Allergy Clin. Immunol.</i> 97: 812-821, 1996.</p> <p>*Hoffman, et al., "Allergens in Bee Venom, III. Identification of Allergen B of Bee Venom as an Acid Phosphatase", <i>J. Allergy Clin. Immunol.</i> 59(5): 364-366, 1977.</p> <p>*Horiuti, et al., "Variable Expression of Pathogenesis-Related Protein Allergen in Mountain Cedar (<i>Juniperus Ashei</i>) Pollen", <i>The Journal of Immunology</i>, 164: 2188-2192, 2000.</p> <p>*Horner, et al., "Identification of the Allergen Psi c 2 from the Basidiomycete <i>Psilocybe Cubensis</i> as a Fungal Cyclophilin", <i>Int. Arch. Allergy Immunol.</i> 107: 298-300, 1995.</p> <p>*Howard, et al., "Regulation of B-Cell Growth and Differentiation by Soluble Factors", <i>Ann. Rev. Immunol.</i> 1: 307-333, 1983.</p> <p>*Hsu, et al., "Differential Effects of IL-4 and IL-4 and IL-10 on IL-2-Induced IFN-γ Synthesis and Lymphokine-Activated Killer Activity", <i>International Immunology</i>, 4(5): 563-569, 1992.</p> <p>*Ichikawa, et al., "Molecular Cloning, Expression and Modelling of Cat Allergen, Cystatin (Fel d 3), A Cysteine Protease Inhibitor", <i>Clinical and Experimental Allergy</i>, 31: 1279-1286, 2001.</p> <p>*Jankulovic, et al., "Isolation and Biochemical Characterization of a Thaumatin-Like Kiwi Allergen", <i>J. Allergy Clin. Immunol.</i> 110: 805-810, 2002.</p>			

PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0232	IN RE APPLICATION NO.: 10/728,323
		APPLICANT: Caplan	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		FILING DATE: December 4, 2003	GROUP: 1644
<p>*Kalliomaki, et al., "Transforming Growth Factor-β in Breast Milk: A Potential Regular of Atopic Disease at an Early Age", <i>J. Allergy Clin. Immunol.</i> 104(6): 1251-1257, 1999.</p>			
<p>*Kleine-Tebbe, et al., "Severe Oral Allergy Syndrome and Anaphylactic Reactions Caused by a Bet v 1-Related PR-10 Protein in Soybean, SAM22", <i>J. Allergy Clin. Immunol.</i> 110: 797-804, 2002.</p>			
<p>*Kowalski, et al., "Mechanisms of Specific Immunotherapy of Allergic Diseases", <i>Allergy</i>, 53: 485-492, 1998.</p>			
<p>*Ledesman, et al., "Cloning, Expression and Characterization of a Novel Four EF-Hand Ca^{2+} - Binding Protein from Olive Pollen with Allergenic Activity", <i>FEBS Letter</i>, 466: 192-196, 2000.</p>			
<p>*Lee, et al., "Oral Administration of IL-12 Suppresses Anaphylactic Reactions in a Murine Model of Peanut Hypersensitivity", <i>Clinical Immunology</i>, 101(2): 220-228, 2001.</p>			
<p>*Leung, et al., "Effect of Anti-IgE Therapy in Patients with Peanut Allergy", <i>N. Engl. J. Med.</i> 348: 986-993, 2003.</p>			
<p>*Li, et al., "A Murine Model of Peanut Anaphylaxis: T- and B-Cell Responses to a Major Peanut Allergen Mimic Human Responses", <i>J. Allergy Clin. Immunol.</i> 106: 150-158, 2000.</p>			
<p>*Li, et al., "Novel Approaches for the Treatment of Food Allergy", <i>Current Opinion in Allergy and Clinical Immunology</i>, 2: 273-278, 2002.</p>			
<p>*Li, et al., "Engineered Recombinant Peanut Protein and Heat-Killed Listeria Monocytogenes Coadministration Protects Against Peanut-Induced Anaphylaxis in a Murine Model", <i>The Journal of Immunology</i>, 170: 3289-3295, 2003.</p>			
<p>*Li, et al., "Strain-Dependent Induction of Allergic Sensitization Caused by Peanut Allergen DNA Immunization in Mice", <i>The Journal of Immunology</i>, 162: 3045-3052, 1999.</p>			
<p>*Lombardero, et al., "cDNA Sequence Analysis of the Main Olive Allergen, Ole e I", <i>Clinical and Experimental Allergy</i>, 24: 765-770, 1994.</p>			
<p>*Lopata, et al., "Characteristics of Hypersensitivity Reactions and Identification of a Unique 49 kd IgE-Binding Protein (Hal-m-1) in Abalone (<i>Haliotis Midae</i>)", <i>J. Allergy Clin. Immunol.</i> 100: 642-648, 1997.</p>			

PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0232	IN RE APPLICATION NO.: 10/728,323
		APPLICANT: Caplan	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		FILING DATE: December 4, 2003	GROUP: 1644
<p>*Lorentz, et al., "Human Intestinal Mast Cells Produce IL-5 in Vitro Upon IgE Receptor Cross-Linking and In Vivo in the Course of Intestinal Inflammatory Disease" <i>Eur. J. Immunol.</i> 29: 1496-1503, 1999.</p>			
<p>*Melen, et al., "Molecular Cloning of Per a 1 and Definition of the Cross-Reactive Group 1 Cockroach Allergens", <i>J. Allergy Clin. Immunol.</i> 103: 859-864, 1999.</p>			
<p>*Moneo, et al., "Isolation and Characterization of Tha p 1, A Major Allergen from the Pine Processionary Caterpillar <i>Thaumetopoea pityocampa</i>", <i>Allergy</i>, 58: 34-37, 2003.</p>			
<p>*Moneo, et al., "Isolation and Characterization of a Major Allergen from the Fish Parasite <i>Anisakis simplex</i>", <i>J. Allergy Clin. Immunol.</i> 106: 177-182, 2000.</p>			
<p>*Monsalve, et al.. "Detection, Isolation and Complete Amino Acid Sequence of an Aeroallergenic Protein from Rapeseed Flour", <i>Clinical and Experimental Allergy</i>, 27: 833-841, 1997.</p>			
<p>*Morafo, et al., "Genetic Susceptibility to Food Allergy is Linked to Differential T_H^2-T_H^1 Responses in C3H/HeJ and BALB/c Mice", <i>J. Allergy Clin. Immunol.</i> 111: 1122-1128, 2003.</p>			
<p>*Mosmann, et al., "Th1 and Th2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties", <i>Ann. Rev. Immunol.</i> 7: 145-173, 1989.</p>			
<p>*Mutius, et al., "The Environmental Predictors of Allergic Disease", <i>J. Allergy Clin. Immunol.</i> 105: 9-19, 2000.</p>			
<p>*Onishi, et al., "Two-Dimensional Electrophoresis of Malassezia Allergens for Atopic Dermatitis and Isolation of Mal f 4 Homologs with Mitochondrial Malate Dehydrogenase", <i>Eur. J. Biochem.</i> 261: 148-154, 1999.</p>			
<p>*Onizuka, et al., "Purification of the Major Allergen of Red Soft Coral (<i>Dendronephthya nipponica</i>)", <i>Int. Arch. Allergy Immunol.</i> 125: 135-143, 2001.</p>			
<p>*Oppenheimer, et al., "Treatment of Peanut Allergy with Rush Immunotherapy", <i>J. Allergy Clin. Immunol.</i> 90: 256-262, 1992.</p>			
<p>*Paddock, et al., "Identification, Cloning, and Recombinant Expression of Procalin, a Major Triatomine Allergen", <i>The Journal of Immunology</i>, 167: 2694-2699, 2001.</p>			
<p>*Palosuo, et al., "Wheat ω-5 Gliadin is a Major Allergen in Children with Immediate Allergy to Ingested Wheat", <i>J. Allergy Clin. Immunol.</i> 108: 634-638, 2001.</p>			

PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0232	IN RE APPLICATION NO.: 10/728,323
		APPLICANT: Caplan	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		FILING DATE: December 4, 2003	GROUP: 1644
<p>*Pastorello, et al., "The Major Allergen of Sesame Seeds (<i>Sesamum Indicum</i>) is a 2S Albumin", <i>Journal of Chromatography B</i>, 756: 85-93, 2001.</p>			
<p>*Pastorello, et al., "Allergenic Cross-Reactivity Among Peach, Apricot, Plum, and Cherry in Patients with Oral Allergy Syndrome: An In Vivo and in Vitro Study", <i>J. Allergy Clin. Immunol.</i> 94: 699-707, 1994.</p>			
<p>*Pierkes, et al., "Decreased Release of Histamine and Sulfidoleukotrienes by Human Peripheral Blood Leukocytes After Wasp Venom Immunotherapy is Partially Due to Induction of IL-10 and IFN-γ Production of T Cells", <i>J. Allergy Clin. Immunol.</i> 103: 326-332, 1999.</p>			
<p>*Pomes, et al., "Novel Allergen Structures with Tandem Amino Acid Repeats Derived from German and American Cockroach", <i>The Journal of Biological Chemistry</i>, 273(46): 30801-30807, 1998.</p>			
<p>*Ramos, et al., "cDNA Cloning and Expression of Blo t 11, the Blomia Tropicalis Allergen Homologous to Paramyosin", <i>Int. Arch. Allergy Immunol.</i> 126: 286-293, 2001.</p>			
<p>*Rasool, et al., "Cloning, Characterization and Expression of Complete Coding Sequences of Three IgE Binding <i>Malassezia Furfur</i> Allergens, Mal f 7, Mal f 8 and Mal f 9", <i>Eur. J. Biochem.</i> 267: 4355-4361, 2000.</p>			
<p>*Romagnani, et al., "The Role of Lymphocytes in Allergic Disease", <i>J. Allergy Clin. Immunol.</i> 105: 399-408, 2000.</p>			
<p>*Rook, et al., "Give us this Day our Daily Germs", <i>Immunology Today</i>, 19: 113-116, 1998.</p>			
<p>*Saarinen, et al., "Transforming Growth Factor-β1 in Mothers' Colostrum and Immune Responses to Cows' Milk Proteins in Infants with Cows' Milk Allergy", <i>J. Allergy Clin. Immunol.</i> 104: 1093-1098, 1999.</p>			
<p>*Saarne, et al., "Cloning and Characterisation of Two IgE-Binding Proteins, Homologous to Tropomyosin and α-Tubulin, from the Mite <i>Lepidoglyphus Destructor</i>", <i>Int. Arch Allergy Immunol.</i> 130: 258-265, 2003.</p>			
<p>*Sampson, et al., "Fatal and Near-Fatal Anaphylactic Reactions to Food in Children and Adolescents", <i>N. Engl. J. Med.</i> 327: 380-384, 1992.</p>			
<p>*Sampson, Hugh., "Food Allergy. Part 1: Immunopathogenesis and Clinical Disorders", <i>The Journal of Allergy and Clinical Immunology</i>, 103(5): 717-728, 1999.</p>			

PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0232	IN RE APPLICATION NO.: 10/728,323
		APPLICANT: Caplan	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		FILING DATE: December 4, 2003	GROUP: 1644
<p>*Sanchez-Monge, et al., "Isolation and Characterization of Relevant Allergens from Boiled Lentils", <i>J. Allergy Clin. Immunol.</i> 106: 955-961, 2000.</p>			
<p>*Santos, et al., "Cockroach Allergens and Asthma in Brazil: Identification of Tropomyosin as a Major Allergen with Potential Cross-Reactivity with Mite and Shrimp Allergens", <i>J. Allergy Clin. Immunol.</i> 104: 329-337, 1999.</p>			
<p>*Saxena, et al., "cDNA Cloning, Expression and Characterization of an Allergenic L3 Ribosomal Protein of Aspergillus Fumigatus" <i>Clin. Exp. Immunol.</i>, 134: 86-91, 2003.</p>			
<p>*Schade, et al., "Differences In Antigen-Specific T-Cell Responses Between Infants with Atopic Dermatitis with and without Cow's Milk Allergy: Relevance of TH2 Cytokines", <i>J. Allergy Clin. Immunol.</i> 106: 1155-1162, 2000.</p>			
<p>*Shen, et al., "Characterization of Allergens from Penicillium Oxalicum and P. Notatum by Immunoblotting and N-Terminal Amino Acid Sequence Analysis", <i>Clinical and Experimental Allergy</i>, 29: 642-651, 1999.</p>			
<p>*Shen, et al., "Molecular Cloning and Immunological Characterization of the House Dues Mite Allergen Der f 7", <i>Clinical and Experimental Allergy</i>, 25: 1000-1006, 1995.</p>			
<p>*Sicherer, et al., "Prevalence of Peanut and Tree Nut Allergy in the US Determined by a Random Digit Dial Telephone Survey", <i>J. Allergy Clin. Immunol.</i> 103: 559-562, 1999.</p>			
<p>*Smith, et al., "Sequence Polymorphisms and Antibody Binding to the Group 2 Dust Mite Allergens", <i>Int. Arch. Allergy Immunol.</i> 124: 61-63, 2001.</p>			
<p>*Smith, et al., "The Molecular Basis of Antigenic Cross-Reactivity Between the Group 2 Mite Allergens", <i>J. Allergy Clin Immunol.</i> 107: 977-984, 2001.</p>			
<p>*Snapper, et al., "Interferon-γ and B Cell Stimulatory Factor-1 Reciprocally Regulate Ig Isotype Production", <i>Science</i>, 236: 944-947, 1987.</p>			
<p>*Sommergruber, et al., "Molecular Characterization of Dau c 1, the Bet v 1 Homologous Protein from Carrot and its Cross-Reactivity with Bet v 1 and Api g 1", <i>Clinical and Experimental Allergy</i>, 29: 840-847, 1999.</p>			
<p>*Stanley, et al., "Identification and Mutational Analysis of the Immunodominant IgE Binding Epitopes of the Major Peanut Allergen Ara h 2", <i>Archives of Biochemistry and Biophysics</i>, 342(2): 244-253, 1997.</p>			

PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0232	IN RE APPLICATION NO.: 10/728,323
		APPLICANT: Caplan	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		FILING DATE: December 4, 2003	GROUP: 1644
<p>*Strobel, et al., "Immune Responses to Dietary Antigens: Oral Tolerance", <i>Immunology Today</i>, 19: 173-181, 1998.</p> <p>*Strobel, et al., "Oral Tolerance, Systemic Immunoregulation, and Autoimmunity" <i>Ann. N.Y. Acad. Sci.</i> 958: 47-58, 2002.</p> <p>*Tejera, et al., "Identification, Isolation, and Characterization of Ole e 7, a New Allergen of Olive Tree Pollen", <i>J. Allergy Clin Immunol</i>, 104: 797-802, 1999.</p> <p>*Tinghino, et al., "Molecular Characterization of a Cross-Reactive Juniperus Oxycedrus Pollen Allergen, Jun o 2: A Novel Calcium-Binding Allergen", <i>J. Allergy Clin Immunol</i>, 101: 772-777, 1998.</p> <p>*Tsai, et al., "Sequence Analysis and Expression of a cDNA Clone Encoding a 98-kDa Allergen in Dermatophagoides Farinae", <i>Clinical and Experimental Allergy</i>, 29: 1606-1613, 1999.</p> <p>*Turcanu, et al., "Characterization of Lymphocyte Responses to Peanuts in Normal Children, Peanut-Allergic Children, and Allergic Children who Acquired Tolerance to Peanuts", <i>The Journal of Clinical Investigation</i>, 111(7): 1065-1072, 2003.</p> <p>*Weiner, et al., "Oral Tolerance: Immune Mechanisms and Treatment of Autoimmune Diseases", <i>Immunology Today</i>, 18: 335-343, 1997.</p> <p>*Wopfner, et al., "Molecular and Immunological Characterization of Profilin from Mugwort Pollen", <i>Biol. Chem.</i> 383: 1779-1789, 2002.</p> <p>*Wu, et al., "Sequencing Analysis of cDNA Clones Encoding the American Cockroach Cr-PI Allergens", <i>The Journal of Biological Chemistry</i>, 271(30): 17937-17943, 1996.</p> <p>*Wu, et al., "Cloning of the American Cockroach Cr-PII Allergens: Evidence for the Existence of Cross-Reactive Allergens Between Species", <i>J. Allergy Clin. Immunol.</i>, 101: 832-840, 1998.</p> <p>*Wu, et al., "Sequencing and Immunochemical Characterization of the American Cockroach Per a 3 (Cr-PI) Isoallergenic Variants", <i>Molecular Immunology</i>, 34(1): 1-8, 1997.</p> <p>*Xu, et al., "Cloning, Expression and Immunological Characterization of Ory s 1, the Major Allergen of Rice Pollen", <i>Gene</i>, 164: 255-259, 1995.</p> <p>*Yasueda, et al., "Identification and Cloning of Two Novel Allergens from the Lipophilic Yeast, <i>Malassezia Furfur</i>", <i>Biochemical and Biophysical Research Communications</i>, 248: 240-</p>			

PTO-1449 (REV. 8-83)	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET: 2002834-0232	IN RE APPLICATION NO.: 10/728,323
		APPLICANT: Caplan	
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>		FILING DATE: December 4, 2003	GROUP: 1644
	244, 1998.		
	<p>*Yeung, et al., "Heat-Killed Listeria Monocytogenes as an Adjuvant Converts Established Murine Th2-Dominated Immune Responses into Th1-Dominated Responses", <i>The Journal of Immunology</i>, 161: 4146-4152, 1998.</p>		
	<p>*Yi, et al., "Identification of Shared and Unique Immunoglobulin E Epitopes of the Highly Conserved Tropomyosins in Blomia Tropicalis and Dermatophagoides Pteronyssinus", <i>Clin. Exp. Allergy</i>, 32: 1203-1210, 2002.</p>		
	<p>*Yocum, et al., "Epidemiology of Anaphylaxis in Olmsted County: A Population-Based Study", <i>J. Allergy Clin. Immunol.</i> 104: 452-456, 1999.</p>		
	<p>*Yokoyama, et al., "Purification, Identification, and cDNA Cloning of Jun a 2, the Second Major Allergen of Mountain Cedar Pollen", <i>Biochemical and Biophysical Research Communications</i>, 275: 195-202, 2000.</p>		
	<p>*Yu, et al., "Proteomics and Immunological Analysis of a Novel Shrimp Allergen, Pen M 2", <i>The Journal of Immunology</i>, 170: 445-453, 2003.</p>		
EXAMINER	DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

3759537




**BEFORE THE OFFICE OF ENROLLMENT AND DISCIPLINE
UNITED STATES PATENT AND TRADEMARK OFFICE**

LIMITED RECOGNITION UNDER 37 CFR § 10.9(b)

Charles Lyon is hereby given limited recognition under 37 CFR § 10.9(b) as an employee of the Choate, Hall & Stewart law firm to prepare and prosecute patent applications wherein the patent applicant is the client of the Choate, Hall & Stewart law firm, and the attorney or agent of record in the applications is a registered practitioner who is a member of the Choate, Hall & Stewart law firm. This limited recognition shall expire on the date appearing below, or when whichever of the following events first occurs prior to the date appearing below: (i) Charles Lyon ceases to lawfully reside in the United States, (ii) Charles Lyon's employment with the Choate, Hall & Stewart law firm ceases or is terminated, or (iii) Charles Lyon ceases to remain or reside in the United States on an H1B visa.

This document constitutes proof of such recognition. The original of this document is on file in the Office of Enrollment and Discipline of the United States Patent and Trademark Office.

Expires: December 1, 2004



Harry I. Meatz
Director of Enrollment and Discipline